Ludwig Enterprises Receives IRB Approval on Bladder Cancer StudymRNA Technology to Assess Patient Response to BCG Immunotherapy Treatment SPARKS, NV / ACCESSWIRE / January 3, 2023 / (OTC
Recent Posts
- June 21, 2023 Amendment to Form S-1 – Registration Statement Under The Securities Act Of 1933 – Ludwig Enterprises, Inc. – 47,000,000 Shares of Common Stock
- Ludwig Enterprises Announces Stock Listing on the Canadian Stock Exchange
- Ludwig Enterprises mRNA Program Generating Broad Clinical Interest
- Ludwig Enterprises, Inc. Chief Medical Officer Lectures UCF Students on mRNAand Chronic Inflammation
- New Scientific Evidence Suggests How Chronic Illnesses May Be Prevented